Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Current Investments (2022 - 2026)

Compass Therapeutics' Cash & Current Investments history spans 5 years, with the latest figure at $194.7 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 71.98% to $194.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $194.7 million, a 71.98% increase, with the full-year FY2025 number at $209.5 million, up 64.56% from a year prior.
  • Cash & Current Investments hit $194.7 million in Q1 2026 for Compass Therapeutics, down from $209.5 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for CMPX hit a ceiling of $219.9 million in Q3 2025 and a floor of $101.5 million in Q2 2025.
  • Historically, Cash & Current Investments has averaged $160.9 million across 5 years, with a median of $166.2 million in 2023.
  • The widest YoY moves for Cash & Current Investments: up 86.34% in 2025, down 35.7% in 2025.
  • Tracing CMPX's Cash & Current Investments over 5 years: stood at $186.6 million in 2022, then fell by 18.28% to $152.5 million in 2023, then fell by 16.51% to $127.3 million in 2024, then surged by 64.56% to $209.5 million in 2025, then dropped by 7.06% to $194.7 million in 2026.
  • Business Quant data shows Cash & Current Investments for CMPX at $194.7 million in Q1 2026, $209.5 million in Q4 2025, and $219.9 million in Q3 2025.